Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an a4b7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizu-mab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic choles-tatic liver injury.
All Science Journal Classification (ASJC) codes